$ERAS

Erasca (ERAS) received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic cancer. The designation allows for accelerated regulatory review. In a Phase 1 trial, ERAS-0015 showed a 57% response rate in pancreatic cancer patients. The company plans to initiate pivotal trials in 2027. Q2 2026 R&D expenses rose to $35.9M, and net loss widened to $44.1M. Erasca raised $632.5M in July 2026, leaving it with $384.3M in cash.

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.

Erasca (ERAS) reported a wider net loss of $287.223M in Q2 2026 and appointed Charles S. Fuchs as R&D president. The stock trades at $18.10, with 90-day and YTD returns of 55.97% and 404.18%, respectively. Despite a high P/B ratio of 17.5x, the company has no revenue and forecasts losses for the next three years. The article questions whether the stock is overvalued.

Erasca (NasdaqGS:ERAS) reported wider Q2 and first-half 2026 net losses, filed a US$112.34 million ESOP-related shelf registration, disclosed a US securities class action tied to its ERAS-0015 program, and appointed Charles S. Fuchs as president of R&D. The piece discusses how these items affect the ERAS-0015 investment narrative and cites fair value estimates from US$4.96 to US$23.30.

Erasca raised about $891.3M gross across two 2026 public offerings, including $632.5M in an upsized July offering and $258.8M in an upsized January offering. Cash was $384.3M as of June 30. The company says proceeds will fund accelerated development of ERAS-0015 and three potentially registration-enabling studies starting 2027-2028.

Analyst estimates for Erasca, Inc. show the average 12-month price target increased from $22.55 to $22.73, with a range of $18 to $30, according to 11 analysts. Based on the Aug. 11 close, the target suggests about 24% upside. The consensus rating remains “Buy” with 9 Buys, 2 Holds, and 0 Sells.

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Erasca Reports Second Quarter 2026 Business Updates and Financial Results Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC co

Simply Wall St reports Erasca (ERAS) appointed Charles S. Fuchs as president of R&D, citing his oncology and biopharma background. The article notes ERAS shares fell 1.6% over one day and 2.2% over a month, while showing strong YTD and 1-year returns. It highlights a 16x price-to-book versus industry 2.5x and peers 11.9x, with zero revenue and a $277.02M net loss.

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of President, Research & Development Effective August 10, 2026, Charles S. Fuchs, M.D., M.P.H., was appointed P

Mizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).